Public Survey and Survival Data Do Not Support Recommendations to Discontinue Prostate-specific Antigen Screening in Men at Age 75

Caire, Arthur; Sun, Leon; Robertson, Cary N.; Polascik, Thomas J.; Maloney, Kelly E.; George, Daniel J.; Price, Marva M.; Stackhouse, Danielle A.; Lack, Benjamin D; Albala, David; Moul, Judd W.

doi:10.1016/j.urology.2009.06.091

Cited by 7 publications

(1 citation statement)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, a large proportion (78 %) of patients disagreed with this recommendation [19], and it ultimately did not lead to changes in clinical practice as investigated by Scosyrev et al [20]. They specifically examined the frequency of PSA testing in men aged ≥75 years in the Behavioral Risk Factor Surveillance System (BRFSS) from 2006 (n=9033), 2008 (n=12063) and 2010 (n=14782).…”

Section: Screening and The Elderlymentioning

confidence: 99%

The Utility of Prostate-Specific Antigen Screening and Prostate Cancer Treatment in Elderly Patients

Vellekoop

Loeb

2013

Curr Transl Geriatr Exp Gerontol Rep

View full text Add to dashboard Cite

Screening and treatment of prostate cancer remain controversial, particularly for elderly men. Since the previous United States Preventive Services Task Force recommendation in 2008 against prostate-specific antigen (PSA) screening after age 75 years, there has not been a substantial reduction in the frequency of PSA testing in this age group. A substantial proportion of elderly men are overdiagnosed and overtreated. On the other hand, men aged >75 years have more aggressive disease. Although screening has questionable benefit for elderly men with significant comorbidities, healthy men >75 years may benefit from definitive therapy. This review discusses prostate cancer screening and management decisions for elderly men, including the use of nomograms and predictive tools for life expectancy.

show abstract

Section: Screening and The Elderlymentioning

confidence: 99%